ライフサイエンスコーパス: interferon beta-1a

1 mpared with three (2%) patients treated with interferon beta 1a.

2 uzumab versus 85 (45%) patients treated with interferon beta 1a.

3 crelizumab and in 2.9% of those treated with interferon beta-1a.

4 o-controlled, multicenter phase III trial of interferon beta-1a.

5 ng were higher with daclizumab HYP than with interferon beta-1a.

6 crelizumab and in 0.2% of those treated with interferon beta-1a.

7 rophy in high risk CIS patients treated with interferon beta-1a.

8 bility after treatment with alemtuzumab than interferon beta-1a.

9 relapse rates and MRI outcomes compared with interferon beta-1a.

10 le sclerosis, as compared with intramuscular interferon beta-1a.

11 improved after alemtuzumab but not following interferon beta-1a.

12 part of a clinical trial of natalizumab and interferon beta-1a.

13 ltiple sclerosis patients being treated with interferon-beta-1a.

14 rate was lower with daclizumab HYP than with interferon beta-1a (0.22 vs. 0.39; 45% lower rate with d

15 5% CI 43.2-60.7%) than patients treated with interferon beta-1a (15 of 66 patients, 27.2%, 17.2-41.4%

16 eeks was lower with daclizumab HYP than with interferon beta-1a (4.3 vs. 9.4; 54% lower number of les

17 ompared with 52 of 107 patients treated with interferon beta-1a (42.6%, 32.4-52.4%; hazard ratio [HR]

18 stratified by site, to receive subcutaneous interferon beta 1a 44 mug, intravenous alemtuzumab 12 mg

19 us alemtuzumab 12 mg per day or subcutaneous interferon beta 1a 44 mug.

20 andomly assigned in a 1:1:1 ratio to receive interferon beta-1a (44 mug subcutaneously three times pe

21 Interferon beta-1a, 6.0 million units (30 micrograms inv

22 gnificantly lower with ocrelizumab than with interferon beta-1a (9.1% vs. 13.6%; hazard ratio, 0.60;

23 eficial effects of alemtuzumab compared with interferon beta-1a across all analysed patient subsets,

24 usly at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a do

25 e of relapse over a two-year period than was interferon beta-1a alone (0.34 vs. 0.75, P<0.001) and wi

26 eta-1a was significantly more effective than interferon beta-1a alone in patients with relapsing mult

27 with combination therapy and 29 percent with interferon beta-1a alone.

28 Patients treated with interferon beta-1a also had significantly fewer exacerba

29 se of either 1.25 or 0.5 mg or intramuscular interferon beta-1a (an established therapy for multiple

30 187 (96%) of 195 patients randomly allocated interferon beta 1a and 376 (97%) of 386 patients randoml

31 202 (87%) of 231 patients randomly allocated interferon beta 1a and 426 (98%) of 436 patients randoml

32 kly intramuscular injections of 30 microg of interferon beta-1a and 190 were assigned to receive week

33 764 patients were randomly assigned: 386 to interferon beta-1a and 378 to glatiramer acetate.

34 vous system, developed during treatment with interferon beta-1a and a selective adhesion-molecule blo

35 Interferon beta-1a and glatiramer acetate are commonly p

36 There was no significant difference between interferon beta-1a and glatiramer acetate in the primary

37 ion of disability compared with subcutaneous interferon beta-1a, and the mean expanded disability sta

38 however, in patients who initially received interferon beta-1a, ARR was lower after switching to fin

39 ose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 mug three times weekl

40 Initiating treatment with interferon beta-1a at the time of a first demyelinating

41 ive of this work was to assess the effect of interferon beta-1a (Avonex) on the rate of development o

42 rpose of this study was to determine whether interferon beta-1a could slow the progressive, irreversi

43 ecific for interleukin-10, as treatment with interferon-beta-1a did not result in accumulation of tra

44 that has demonstrated superior efficacy over interferon beta-1a for relapsing-remitting multiple scle

45 40 (20%) patients in the interferon beta 1a group had sustained accumulation of d

46 20 (11%) of patients in the interferon beta 1a group had sustained accumulation of d

47 75 (40%) patients in the interferon beta 1a group relapsed (122 events) compared

48 104 (51%) patients in the interferon beta 1a group relapsed (201 events) compared

49 94 (47%) patients in the interferon beta 1a group were relapse-free at 2 years co

50 plan-Meier estimates, 59% of patients in the interferon beta 1a group were relapse-free at 2 years co

51 mpared with 134 [66%] of 202 patients in the interferon beta 1a group) that were mostly mild-moderate

52 adverse events compared with 12 (6%) in the interferon beta 1a group, and three (1%) had immune thro

53 e thrombocytopenia compared with none in the interferon beta 1a group.

54 mmon in the daclizumab HYP group than in the interferon beta-1a group (in 65% vs. 57% of the patients

55 ower than expected: 258 patients (126 in the interferon beta-1a group and 132 in the glatiramer aceta

56 tients in the placebo group, patients in the interferon beta-1a group had a relative reduction in the

57 ple sclerosis was significantly lower in the interferon beta-1a group than in the placebo group (rate

58 lizumab HYP group and in 10% of those in the interferon beta-1a group.

59 Interferon beta-1a had a significant beneficial impact i

60 cing lesions, although patients treated with interferon beta-1a had significantly fewer gadolinium-en

61 Pegylated interferon beta-1a has shown efficacy in a phase 3 trial

62 ertaken to determine whether combined use of interferon beta-1a (IFN) 30 mug intramuscularly weekly a

63 clerosis (SENTINEL) study, patients received interferon beta-1a (IFN-beta-1a) plus natalizumab 300 mg

64 nal changes in the biopharmaceutical product interferon beta-1a (IFN-beta-1a).

65 A systematic mutational analysis of human interferon-beta-1a (IFN-beta) was performed to identify

66 We tested whether interferon-beta-1a (IFN-beta-1a), which increases CD73 s

67 monotherapy in AFFIRM or in combination with interferon beta-1a (IFNbeta) in SENTINEL.

68 t benefits of fingolimod 0.5 or 1.25 mg over interferon beta-1a (IFNbeta-1a) in patients with relapsi

69 To evaluate the effects of interferon beta-1a (IFNbeta-1a, 30 microg administered i

70 nter, phase III, placebo-controlled study of interferon beta-1a (IFNbeta-1a; AVONEX) in relapsing for

71 arison, SPMS subjects from the intramuscular interferon beta-1a (IM IFNbeta-1a) IMPACT study were als

72 fety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial.

73 disability, comparing alemtuzumab 12 mg and interferon beta 1a in all patients who received at least

74 cacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite

75 o-controlled clinical effectiveness trial of interferon beta 1a in the treatment of IPF.

76 and accumulation of disability compared with interferon beta-1a in a phase 2 trial.

77 od before randomization to receive continued interferon beta-1a in combination with 300 mg of nataliz

78 zumab reduced disease activity compared with interferon beta-1a in most of the analysed subgroups.

79 Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting

80 Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing-Remitting

81 e safe and effective alone and when added to interferon beta-1a in preliminary studies.

82 ibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitti

83 se rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0.16 vs. 0.29; 46% lower

84 n was 0.02 with ocrelizumab versus 0.29 with interferon beta-1a in trial 1 (94% lower number of lesio

85 ment) significantly favored ocrelizumab over interferon beta-1a in trial 2 (0.28 vs. 0.17, P=0.004) b

86 me the fourth study of the beta interferons (interferon-beta-1a, in this case) to demonstrate a parti

87 Intramuscular injections of interferon-beta-1a increased serum levels of interleukin

88 Interferon-beta-1a induced accumulation of interleukin-1

89 Interferon beta-1a is beneficial when initiated at the f

90 on natalizumab monotherapy >18 months, 6 on interferon beta-1a monotherapy >36 months, and 5 untreat

91 of the study was to determine the effect of interferon-beta-1a on the expression of interleukin-10,

92 within the brain were randomized to receive interferon beta-1a or placebo after initial treatment wi

93 weekly intramuscular injections of 30 microg interferon beta-1a or placebo.

94 fingolimod at a dosage of 0.5 or 1.25 mg/d, interferon beta-1a, or placebo.

95 tes of disease activity and progression than interferon beta-1a over a period of 96 weeks.

96 eks was 16% with daclizumab HYP and 20% with interferon beta-1a (P=0.16).

97 At the 3-year point patients treated with interferon beta-1a showed a 50% less risk of CDMS.

98 In contrast, those treated with interferon beta-1a steadily accumulated disability.

99 uced compared with the previous 12 months of interferon beta-1a therapy (p<0.0001 for T2 lesions at b

100 randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at least one relapse

101 re randomised to receive 44 mug subcutaneous interferon beta-1a three times per week or 20 mg subcuta

102 olimod compared with the previous 12 months (interferon beta-1a to 0.5 mg fingolimod [n=167], 0.31 [9

103 s 0.22 [0.15-0.31], in months 13-24 p=0.049; interferon beta-1a to 1.25 mg fingolimod [n=174], 0.29 [

104 Switching from interferon beta-1a to fingolimod led to enhanced efficac

105 tients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24

106 Compared with patients switched from interferon beta-1a to fingolimod, continuous treatment w

107 s compared with the group that switched from interferon beta-1a to fingolimod, we recorded lower ARRs

108 34.9% in the placebo group and 21.9% in the interferon beta-1a-treated group.

109 0 in placebo-treated patients versus 0.61 in interferon beta-1a-treated patients.

110 tively evaluated the effect of intramuscular interferon beta-1a treatment following the first demyeli

111 enrolled in the Observational Study of Early Interferon beta-1a Treatment in High Risk Subjects after

112 Interferon beta-1a treatment produced a significant dela

113 Interferon beta 1a was given three-times per week and al

114 Interferon beta 1a was given three-times per week and al

115 Natalizumab added to interferon beta-1a was significantly more effective than

116 The effect of interferon-beta-1a was relatively specific for interleuk

117 ginally received 30 mug weekly intramuscular interferon beta-1a were randomly reassigned (1:1) to rec

118 n Relapsing MS Disease) study was to compare interferon beta-1a with glatiramer acetate in patients w

119 umab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse